Source: Zacks

Immune Design: Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates

Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

Read full article »
Immune Design's Competitors | Immune Design's News | Immune Design's Financials
Stay up-to-date with the latest news on Immune Design
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Carlos Paya's photo - President & CEO of Immune Design

President & CEO

Carlos Paya

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Immune Design